Reuters logo
BRIEF-Biocartis Group announces CE-marking of its Idylla NRAS-BRAF mutation test
December 15, 2016 / 6:18 AM / a year ago

BRIEF-Biocartis Group announces CE-marking of its Idylla NRAS-BRAF mutation test

Dec 15 (Reuters) - Biocartis Group Nv :

* Biocartis Group: CE-marking Idylla NRAS-BRAF mutation test completes offering of metastatic colorectal cancer tests for clinical use on Idylla platform Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below